TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11223708

Group type: EXPERIMENTAL
Intervention: Endometrial thermal balloon ablation under local anesthesia
Number of subjects: 93

Group type: COMPARATOR
Intervention: Endometrial roller ball ablation under general anesthesia
Number of subjects: 93
Study: 8688774

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone 0.15 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 1747553

Group type: EXPERIMENTAL
Intervention: Intensive education group
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual education group
Number of subjects: 104
Study: 7037048

Group type: EXPERIMENTAL
Intervention: Complan meal (2.1 MJ)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Complan meal (4.2 MJ)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ephedrine (0.25 mg/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ephedrine (0.50 mg/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water control
Number of subjects: 16
Study: 30802186

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Thrombus length (measured using susceptibility vessel sign on T2* imaging)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Susceptibility vessel sign length
Number of subjects: 97
Study: 27362838

Group type: EXPERIMENTAL
Intervention: Induction of reduced loneliness
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Induction of increased loneliness
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study: 26170627

Group type: EXPERIMENTAL
Intervention: Lesinurad (oral solution) 5 mg to 600 mg (single ascending dose)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lesinurad (oral solution or immediate-release capsules) 100 mg to 400 mg once daily for 10 days (multiple ascending dose)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lesinurad (tablets or capsules)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lesinurad (general)
Number of subjects: 66
Study: 24290413

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/hydrochlorothiazide (HCTZ)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HCTZ
Number of subjects: 40

Group type: COMPARATOR
Intervention: Test and reference products
Number of subjects: 40
Study: 21778269

Group type: EXPERIMENTAL
Intervention: Heterochromatic flicker electroretinograms (ERGs) at 36 Hz and 12 Hz
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Heterochromatic flicker electroretinograms (ERGs) at 36 Hz
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Heterochromatic flicker electroretinograms (ERGs) at 12 Hz
Number of subjects: 32

Group type: COMPARATOR
Intervention: Heterochromatic flicker electroretinograms (ERGs)
Number of subjects: 32
Study: 19101249

Group type: EXPERIMENTAL
Intervention: Faculty-directed training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Self-directed training
Number of subjects: 45
Study: 17300603

Group type: EXPERIMENTAL
Intervention: 2.5% sodium deoxycholate (SD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1% sodium deoxycholate (SD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15096902

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 11779730

Group type: EXPERIMENTAL
Intervention: Propofol (6 microM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol with ascorbic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study: 9821420

Group type: EXPERIMENTAL
Intervention: 5-day regimen of amoxicillin/clavulanate in 3 divided doses
Number of subjects: 385

Group type: COMPARATOR
Intervention: 10-day regimen of amoxicillin/clavulanate in 3 divided doses
Number of subjects: 385
Study: 7654110

Group type: EXPERIMENTAL
Intervention: velnacrine maleate 150 mg/d
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: velnacrine maleate 225 mg/d
Number of subjects: 449

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 449
Study: 2195978

Group type: EXPERIMENTAL
Intervention: Labetalol (1, 2, then 3 tablets/day, adjusted according to BP)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Nifedipine (2 tablets/day, recommended dosage)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 170

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 170
Study: 371342

Group type: EXPERIMENTAL
Intervention: Oral glucose administration
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous glucose administration
Number of subjects: 6
Study: 31983158

Group type: EXPERIMENTAL
Intervention: 10-day course of triple therapy (Rabeprazole 20 mg, Amoxicillin 1,000 mg, Clarithromycin 500 mg twice daily for 10 days plus 4 days placebo)
Number of subjects: 75

Group type: COMPARATOR
Intervention: 14-day course of triple therapy (Rabeprazole 20 mg, Amoxicillin 1,000 mg, Clarithromycin 500 mg twice daily for 14 days)
Number of subjects: 75
Study: 29750251

Group type: EXPERIMENTAL
Intervention: EAA + AE
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: AE
Number of subjects: 50

Group type: COMPARATOR
Intervention: EAA
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo + AE
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 28178355

Group type: EXPERIMENTAL
Intervention: Exercise training for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 25666737

Group type: EXPERIMENTAL
Intervention: Prior tobacco counseling experiences (at least one 5A)
Number of subjects: 1266

Group type: EXPERIMENTAL
Intervention: Prior tobacco counseling experiences
Number of subjects: 1266

Group type: COMPARATOR
Intervention: No prior tobacco counseling experiences
Number of subjects: 1266
Study: 24296324

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 77

Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 77
Study: 21410949

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Palpation-guided surgery
Number of subjects: 120
Study: 19132203

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg daily (S80; n = 16)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg and Simvastatin 10 mg daily (E10/S10; n = 16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 32
Study: 17846352

Group type: EXPERIMENTAL
Intervention: Hispanic whites
Number of subjects: 32642

Group type: EXPERIMENTAL
Intervention: Hispanic blacks
Number of subjects: 32642

Group type: COMPARATOR
Intervention: Non-Hispanic whites
Number of subjects: 32642

Group type: COMPARATOR
Intervention: Non-Hispanic blacks
Number of subjects: 32642

Group type: COMPARATOR
Intervention: Hispanic whites vs Non-Hispanic whites
Number of subjects: 32642

Group type: COMPARATOR
Intervention: Hispanic blacks vs Non-Hispanic whites
Number of subjects: 32642

Group type: COMPARATOR
Intervention: Non-Hispanic blacks vs Non-Hispanic whites
Number of subjects: 32642
Study: 15562917

Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline (20 mg, b.i.d.) for 3 months plus scaling and root planing (SRP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (b.i.d.) for 3 months plus scaling and root planing (SRP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison between LDD and placebo groups
Number of subjects: 30
Study: 11686749

Group type: EXPERIMENTAL
Intervention: Solution-focused brief therapy (SFBT) training
Number of subjects: 0
Study: 9159625

Group type: EXPERIMENTAL
Intervention: Low-intensity oral anticoagulants (INR 2.5 to 3.5) plus aspirin (100 mg/day)
Number of subjects: 503

Group type: COMPARATOR
Intervention: High-intensity oral anticoagulants (INR 3.5 to 4.5)
Number of subjects: 503
Study: 7966259

Group type: EXPERIMENTAL
Intervention: Medication placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncontrolled demand characteristics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled demand characteristics
Number of subjects: 0
Study: 2882183

Group type: EXPERIMENTAL
Intervention: Halothane in 30% oxygen/70% nitrous oxide (n = 37)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Halothane in 100% oxygen (n = 17)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Isoflurane in 30% oxygen/70% nitrous oxide (n = 17)
Number of subjects: 71
Study: 29430839

Group type: EXPERIMENTAL
Intervention: Carnosine supplementation (500 mg per day for 2 months)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (500 mg per day for 2 months)
Number of subjects: 43
Study: 27240178

Group type: EXPERIMENTAL
Intervention: cellex
Number of subjects: 246

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 246
Study: 25643496

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (ES)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Endoscopic balloon dilatation (EBD)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Combined technique of ES followed by EBD
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 76
Study: 23161302

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2a (180 μg weekly)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (non-advanced liver disease)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Advanced liver disease group
Number of subjects: 58
Study: 19176796

Group type: EXPERIMENTAL
Intervention: Ferumoxytol (two injections of 510 mg within 7 days)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Oral iron (200 mg elemental daily for 21 days)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Number of subjects: 230
Study: 17495576

Group type: EXPERIMENTAL
Intervention: Integrated communication skills training program
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 129
Study: 14693624

Group type: EXPERIMENTAL
Intervention: Ambulation with epidural analgesia (0.08% bupivacaine‐epinephrine plus 1 microg/mL of sufentanil)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ambulation with epidural analgesia
Number of subjects: 61

Group type: COMPARATOR
Intervention: Recumbent with epidural analgesia
Number of subjects: 61
Study: 11779898

Group type: COMPARATOR
Intervention: N-acetylaspartate (NAA)/choline ratio in noninfarcted regions in the symptomatic hemisphere (1.73+/‐0.16)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Lactate/NAA ratio in the symptomatic hemisphere (0.04+/‐0.08)
Number of subjects: 44

Group type: COMPARATOR
Intervention: NAA/choline ratio in both the symptomatic and asymptomatic hemispheres
Number of subjects: 44
Study: 9640120

Group type: EXPERIMENTAL
Intervention: Premedication with diazepam alone (group 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Premedication with diazepam and alfentanil (group 3)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No premedication (group 1)
Number of subjects: 45
Study: 7978521

Group type: EXPERIMENTAL
Intervention: Cervical headgear/tandem mechanics
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Bionator appliance
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (Bolton Study)
Number of subjects: 190
Study: 2556727

Group type: EXPERIMENTAL
Intervention: Intravenous alprazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 5134998

Group type: EXPERIMENTAL
Intervention: Dimethyltriazeno imidazole carboxamide, 2.0 mg/kg for 10 days
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Dimethyltriazeno imidazole carboxamide, 4.5 mg/kg for 10 days
Number of subjects: 155
Study: 31785626

Group type: EXPERIMENTAL
Intervention: Post-cervical artificial insemination (PCAI; 1.5 × 10^9 spermatozoa/45 mL)
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Post-cervical artificial insemination (PCAI)
Number of subjects: 644

Group type: COMPARATOR
Intervention: Cervical artificial insemination (CAI; 3 × 10^9 spermatozoa/90 mL)
Number of subjects: 644
Study: 28292775

Group type: EXPERIMENTAL
Intervention: PPV with ILM peeling combined with macular buckle under direct vision (group 2, n=46)
Number of subjects: 98

Group type: COMPARATOR
Intervention: PPV with ILM peeling (group 1, n=52)
Number of subjects: 98
Study: 27442000

Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency thermocoagulation denervation on the lumbar facet joint
Number of subjects: 80

Group type: COMPARATOR
Intervention: Injection of betamethasone and lidocaine into the lumbar facet joint
Number of subjects: 80
Study: 25118962

Group type: EXPERIMENTAL
Intervention: Bushen Yiqi (BY) granule
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Bushen Fangchuan (BF) tablet
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 22238571

Group type: EXPERIMENTAL
Intervention: Increased cerebro-cerebral coherence between contralateral M1 and SMA during movement preparation and execution in GTS patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study: 21034892

Group type: EXPERIMENTAL
Intervention: Covered stent
Number of subjects: 400

Group type: COMPARATOR
Intervention: Uncovered stent
Number of subjects: 400
Study: 17522246

Group type: EXPERIMENTAL
Intervention: BSC plus panitumumab, 6 mg/kg i.v., every other week
Number of subjects: 463

Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 463
Study: 15855226

Group type: EXPERIMENTAL
Intervention: IRI/LV/5‐FU
Number of subjects: 295

Group type: COMPARATOR
Intervention: OXA/LV/5‐FU
Number of subjects: 295
Study: 11955909

Group type: EXPERIMENTAL
Intervention: Laser in situ keratomileusis (LASIK)
Number of subjects: 59
Study: 9802454

Group type: EXPERIMENTAL
Intervention: H. pylori eradication in patients with DU
Number of subjects: 103

Group type: COMPARATOR
Intervention: H. pylori-positive patients with DU
Number of subjects: 103

Group type: COMPARATOR
Intervention: H. pylori-negative patients with DU
Number of subjects: 103
Study: 8583263

Group type: EXPERIMENTAL
Intervention: Computer-generated feedback to physicians about the patient's functional status and educational sessions for physicians
Number of subjects: 557
Study: 2669935

Group type: EXPERIMENTAL
Intervention: Bed-rest in hospital
Number of subjects: 139

Group type: COMPARATOR
Intervention: Conventional outpatient management
Number of subjects: 139
Study: 837962

Group type: EXPERIMENTAL
Intervention: Doxantrazole 200 mg taken orally 1 hour before exercise test
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Doxantrazole 400 mg taken orally
Number of subjects: 13
Study: 31805571

Group type: EXPERIMENTAL
Intervention: Tamsulosin (TAM) + Serenoa repens (SR) 320 mg/day + Bovine Colostrum (BC) 30 mg/day
Number of subjects: 148

Group type: COMPARATOR
Intervention: Tamsulosin (TAM) only
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Tamsulosin (TAM) + Serenoa repens (SR) + Bovine Colostrum (BC)
Number of subjects: 148
Study: 31060549

Group type: EXPERIMENTAL
Intervention: Standardized aqueous extract of Phyllanthus emblica (P. emblica) 250 mg twice daily
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Standardized aqueous extract of Phyllanthus emblica (P. emblica) 500 mg twice daily
Number of subjects: 59
Study: 28928175

Group type: EXPERIMENTAL
Intervention: Integrated AF management involving a trained practice nurse and collaboration with secondary care
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 1000
Study: 25769436

Group type: EXPERIMENTAL
Intervention: Natural cocoa consumption (12.7 g natural cocoa, 148 kcal/serving) for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cocoa-free placebo for 4 weeks
Number of subjects: 24
Study: 23826659

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Neurohormonal response
Number of subjects: 170
Study: 22156664

Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond (PB; Kuraray Medical)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE; Kuraray Medical)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both primers (PB and SE)
Number of subjects: 52
Study: 19573330

Group type: EXPERIMENTAL
Intervention: Diffractive multifocal intraocular lens
Number of subjects: 65

Group type: COMPARATOR
Intervention: Monofocal intraocular lens
Number of subjects: 65
Study: 17893628

Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Morphine administration
Number of subjects: 308
Study: 14959818

Group type: EXPERIMENTAL
Intervention: 30% Supplemental Oxygen (SuppO2)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Compressed Air (CA)
Number of subjects: 70
Study: 11575487

Group type: EXPERIMENTAL
Intervention: Search version of medical scenarios (information pursued after some information was missing)
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Simple version of medical scenarios (information received from the start)
Number of subjects: 1206
Study: 9640556

Group type: EXPERIMENTAL
Intervention: Sunscreen preparations containing protective ingredients (dimethicone and cyclomethicone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunscreen preparations without protective ingredients
Number of subjects: 0
Study: 7527592

Group type: EXPERIMENTAL
Intervention: ifosfamide/carboplatin/etoposide (ICE)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Hematopoietic growth factor administration
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells primed with cyclophosphamide and granulocyte colony-stimulating factor
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Platelet recovery
Number of subjects: 115
Study: 3052065

Group type: EXPERIMENTAL
Intervention: Folic acid treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 31219315

Group type: EXPERIMENTAL
Intervention: Computed tomography
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard care (serial examination with or without ultrasound)
Number of subjects: 68
Study: 28893866

Group type: EXPERIMENTAL
Intervention: FK506 (tacrolimus) therapy with target levels <2, 2-3, and 3-5 ng·mL-1
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: FK506 (tacrolimus) therapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 26265421

Group type: EXPERIMENTAL
Intervention: 8-week walking/running aerobic exercise program
Number of subjects: 46

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 46
Study: 22538374

Group type: EXPERIMENTAL
Intervention: Three-tone AXB paradigm with varying intensity levels of tone X (closer to Tone A or B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preceding AXB patterns with null intensity context sequences
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preceding AXB patterns with coherent intensity context sequences
Number of subjects: 0
Study: 21257115

Group type: EXPERIMENTAL
Intervention: Early adolescence depressive symptoms
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: High depressive symptoms with increases in impulsivity
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: High impulsivity with increases in depressive symptoms
Number of subjects: 678

Group type: COMPARATOR
Intervention: Nongamblers and social gamblers
Number of subjects: 678
Study: 19920417

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% (150 mg)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Levobupivacaine 0.33% (99 mg)
Number of subjects: 86
Study: 17047644

Group type: COMPARATOR
Intervention: Three courses of carboplatin (AUC 4) and vinorelbine (25 mg/m²)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Six courses of carboplatin (AUC 4) and vinorelbine (25 mg/m²)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Three courses of carboplatin and vinorelbine
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Six courses of carboplatin and vinorelbine
Number of subjects: 297
Study: 15130190

Group type: EXPERIMENTAL
Intervention: Noncontingent success
Number of subjects: 72

Group type: COMPARATOR
Intervention: Noncontingent failure
Number of subjects: 72
Study: 10938488

Group type: EXPERIMENTAL
Intervention: NYHA classification
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Goldman Activity Scale Classification (GASC)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Peak O(2) consumption (pVO(2))
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Anaerobic threshold (AT)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 6‐min walk test (6‐MWT)
Number of subjects: 143
Study: 9493672

Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV) with BiPAP 1.2/0.5 kPa
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV) with BiPAP 1.6/0.5 kPa
Number of subjects: 18
Study: 8335701

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3772801

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (C)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Decaffeinated coffee (D)
Number of subjects: 9
Study: 29170486

Group type: EXPERIMENTAL
Intervention: Large-particle size emulsion (LPE) - diameter 0.759 μm, 10 g lipid emulsion, 190 g yoghurt
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Small-particle size emulsion (SPE) - diameter 0.290 μm, 10 g lipid emulsion, 190 g yoghurt
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control non-emulsion (NE) - 10 g non-emulsion lipid, 190 g yoghurt
Number of subjects: 20
Study: 26267219

Group type: EXPERIMENTAL
Intervention: Rupatadine (1 mg/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desloratadine (0.5 mg/ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rupatadine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active treatments (Rupatadine and Desloratadine)
Number of subjects: 0